Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 592 participants.

Also called NCT02884206

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 592 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT02884206
  • EudraCT 2016-001254-17
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Argentina, Australia, Belgium, Bulgaria, Canada, Croatia, France, Germany, Italy, Lithuania, Netherlands, Poland, Russia, South Korea, Spain, Switzerland, Taiwan, Türkiye, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT02884206. Randomized; double masking; primary purpose treatment. Start 2016-11-23 (actual); primary completion 2022-05-16 (actual). Results posted on 2024-08-06.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Efficacy and Safety of LCZ696 Compared to Valsartan on Cognitive Function in Patients With Chronic Heart Failure and Preserved Ejection Fraction
Acronym
PERSPECTIVE
Condition
Chronic Heart Failure (CHF)
Intervention (Drug)
LCZ696
Intervention (Drug)
Valsartan
Intervention (Drug)
Placebo of LCZ696
Intervention (Drug)
Placebo of Valsartan
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct02884206
Content hash
0215804bb3aeb33eb070e5adc54732d4d4747c6b7598283cbd86a11f34bd0873